Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bexicaserin
Dravet Syndrome
Longboard Pharmaceuticals
P3
BB
(66)
Blinatumomab
Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
P3
BB
(66)
Bl-M07D1
Non-Small Cell Lung Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P3
BB
(66)
Brentuximab Vedotin
Mycosis Fungoides
University of Alabama at Birmingham
P3
BB
(66)
Busulfanum
Diffuse Large B-Cell Lymphoma
Sichuan University
P3
BB
(66)
Cabozantinib
Castration-Resistant Prostate Carcinoma
Rana McKay, MD
P3
BB
(66)
Capecitabine
Renal Cell Carcinoma
Oliver Jonas
P3
BB
(66)
Capecitabine
Digestive System Neoplasm
China Medical University, China
P3
BB
(66)
Capecitabine
Metastasis From Malignant Tumor Of Colon
Jun Huang
P3
BB
(66)
Capecitabine
Colon Adenocarcinoma
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
P3
BB
(66)
Carboplatin
Adenosquamous Lung Carcinoma
NRG Oncology
P3
BB
(66)
Carboplatin
B-Cell Non-Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
P3
BB
(66)
Carboplatin
Urinary Bladder Carcinoma
G1 Therapeutics, Inc.
P3
BB
(66)
Carboplatin
Breast Neoplasm
BioNTech SE
P3
BB
(66)
Carboplatin
Head And Neck Cancer
Rapa Therapeutics LLC
P3
BB
(66)
Carboplatin
HER2 Positive Breast Carcinoma
Rutgers, The State University of New Jersey
P3
BB
(66)
Carboplatin
Invasive Breast Carcinoma
Baylor Breast Care Center
P3
BB
(66)
Carboplatin
Metastatic Prostate Carcinoma
Case Comprehensive Cancer Center
P3
BB
(66)
Carboplatin
Ovarian Brenner Tumor
Gynecologic Oncology Group
P3
BB
(66)
Carboplatin
Respiratory System Disorder
Nanfang Hospital, Southern Medical University
P3
BB
(66)
Cediranib
Acute Myeloid Leukemia With 11q23 Abnormalities
Alice Mims
P3
BB
(66)
Cediranib
Fallopian Tube Transitional Cell Carcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Cediranib
Ovarian Seromucinous Carcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Cediranib
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Cediranib
Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Showing 2126 to 2150 of 42,301 assets
Previous
Page 86 of 1693
Next